Analysis of K-ras gene codon 12 mutation in pancreatic tissue of patients with pancreatic cancer

Ovo istraživanje je imalo za cilj da se analizira prisustvo mutacije u kodonu 12 gena K-ras u pankreasnom tkivu pacijenata sa karcinomom pankreasa i da se proceni da li ova mutacija predstavlja potencijalni molekularni marker za karcinom pankreasa u srpskoj populaciji. Istraživanje je obuhvatilo analizu 40 uzoraka tkiva pankreasa pacijenata sa kliničkom dijagnozom karcinoma pankreasa. Prisustvo mutacije u kodonu 12 gena K-ras analizirano je metodom PCR-RFLP (polymerase chain reaction - restriction fragment length poly­morphism). Rezultati istraživanja ukazuju da je mutacija u kodonu 12 gena K-ras u tkivu pankreasa prisutna sa visokom učestalošću (66 %) kod pacijenata sa karcinomom pankreasa.The aim of this study was to analyze K-ras codon 12 mutation in the pancreatic tissue of Serbian patients with pancreatic cancer and assess whether the given mutation can be used as a molecular marker for this disease. The study was performed on pancreatic tissue samples obtained from 40 patients with clinical diagnosis of pancreatic cancer. The presence of K-ras codon 12 mutation was analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Our study showed that K-ras mutation is present with a high frequency (66%) in the pancreatic tissue of patients with pancretic cancer

ANALYSIS OF K-RAS GENE CODON 12 MUTATION IN PANCREATIC TISSUE OF PATIENTS WITH PANCREATIC CANCER

Abstract — The aim of this study was to analyze K-ras codon 12 mutation in the pancreatic tissue of Serbian patients with pancreatic cancer and assess whether the given mutation can be used as a molecular marker for this disease. The study was performed on pancreatic tissue samples obtained from 40 patients with clinical diagnosis of pancreatic cancer. The presence of K-ras codon 12 mutation was analyzed by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Our study showed that K-ras mutation is present with a high frequency (66%) in the pancreatic tissue of patients with pancretic cancer